Streetbeat News

Revenues

PCRX

Pacira BioSciences projects its 2024 revenue to be between $680M-$705M, which is below the consensus estimate of $716.62M. The company also anticipates an adjusted gross margin of 74%-76%.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:06 pm

IHRT

iHeartMedia anticipates its Q1 revenue to be flat or decrease by up to 2% compared to the previous estimate of $844.1M. The company expects its Q1 consolidated adjusted EBITDA to range between $100 million and $110 million, an increase from $93 million in the previous year. iHeartMedia remains committed to its long-term target of approximately 4x net debt to adjusted EBITDA.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:06 pm

EWG

Germany's Consumer Price Index (CPI) for February showed a month-on-month increase of 0.4%, which is slightly below the estimated 0.5% but higher than the previous month's 0.2%.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:06 pm

EWG

Germany's Consumer Price Index (CPI) for February showed a year-over-year increase of 2.5%, which is slightly below the estimated 2.6% and down from the previous 2.9%.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:05 pm

TGNA

TEGNA anticipates a decrease in its total company GAAP revenue for Q1'2024, expecting a low-to-mid-single digit percent drop.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:05 pm

IHRT

iHeartMedia (IHRT) reported Q4 sales of $1.07 billion, surpassing the analyst consensus estimate of $1.04 billion by 2.58%. However, this represents a 5.25% decrease from the $1.13 billion sales reported in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 29, 2024 | 1:04 pm

CRNX

Crinetics Pharmaceuticals (NASDAQ:CRNX) has been evaluated by 6 analysts over the past three months, showing a mix of bullish and bearish sentiments. The average 12-month price target is $49.00, indicating an 8.89% increase from the previous target of $45.00. Analysts' actions range from 'Maintain' to 'Raise', with ratings from 'Outperform' to 'Buy'. The company's financials reveal challenges, including a -24.45% revenue decline and a net margin of -16606.36%, indicating potential profitability and cost management issues.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:01 pm

ZUO

In the past three months, Zuora (NYSE:ZUO) received mixed analyst ratings, with a shift towards a neutral stance in the last 30 days. The average 12-month price target for ZUO has increased to $12.4, up from $10.00, indicating a positive outlook from analysts. Zuora's financials show a revenue growth of 8.68% but lag behind industry peers, with challenges in profitability, asset utilization, and a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:01 pm

RXST

Analysts have recently updated their ratings and price targets for RxSight (NASDAQ:RXST), showing a mix of bullish and somewhat bullish opinions. The average 12-month price target has been raised to $47.44, indicating a positive outlook. Key financial indicators reveal RxSight's strong revenue growth but challenges in profitability and asset utilization. The company, focusing on intraocular lens technology post-cataract surgery, shows a positive revenue trend but struggles with net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:00 pm

AVDX

AvidXchange Holdings (NASDAQ:AVDX) has been the subject of 6 analyst ratings over the last three months, showing a mix of opinions. The average 12-month price target for AVDX has increased to $13.17 from $12.25, indicating a positive sentiment shift among analysts. The company has shown a revenue growth of 19.74% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin, ROE, and ROA. Despite these challenges, its debt management appears sound.

Portfolio Pulse from Benzinga Insights

February 29, 2024 | 1:00 pm